<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951741</url>
  </required_header>
  <id_info>
    <org_study_id>B-1502/288-302</org_study_id>
    <nct_id>NCT02951741</nct_id>
  </id_info>
  <brief_title>Revision Total Hip Replacement Arthroplasty and Hematologic Variables</brief_title>
  <official_title>Relations Between Hematologic Variables and Postoperative Bleeding and Transfusion in Revision Total Hip Replacement Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Revision total hip replacement arthroplasty is a surgery having intra- and postoperative
      substantial blood loss. The investigators will investigate the relationship between the
      various hematologic variables and postoperative bleeding volume.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of FIBTEM</measure>
    <time_frame>5 minutes before initiation of anesthesia and 5 minutes after finishing operation</time_frame>
    <description>FIBTEM: one of the measurements of the rotational thromboelastometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume of infused fluid during operation</measure>
    <time_frame>Period from starting to finishing the operation (During operation, an expected average of 3 hours)</time_frame>
    <description>Infused total crystalloid and colloid volume during the operation will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative urine output</measure>
    <time_frame>Period from starting to finishing the operation (During operation, an expected average of 3 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion units</measure>
    <time_frame>Period from starting to finishing the operation (During operation, an expected average of 3 hours) and postoperative first day</time_frame>
    <description>Red blood cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative bleeding volume</measure>
    <time_frame>postoperative 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>postoperative day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>postoperative day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>postoperative day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time_international normalized ratio</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time_international normalized ratio</measure>
    <time_frame>postoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated partial prothrombin time</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated partial prothrombin time</measure>
    <time_frame>postoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen concentration</measure>
    <time_frame>preoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen concentration</measure>
    <time_frame>postoperative day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Avascular Necrosis of Hip</condition>
  <condition>Degenerative Hip Joint Disease</condition>
  <arm_group>
    <arm_group_label>RTHRA group</arm_group_label>
    <description>patients undergoing revision total hip replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RTHRA group</intervention_name>
    <description>hematologic variables measurement in patients undergoing revision total hip replacement</description>
    <arm_group_label>RTHRA group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing revision total hip replacement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  revision total hip replacement

        Exclusion Criteria:

          -  hematologic disease

          -  anticoagulant medication

          -  American Society of Anesthesiologists physical status 4 and 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Seok Na, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Seok Na, MD, PhD</last_name>
    <email>hsknana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoseok Na, pf</last_name>
      <phone>82-31-787-7507</phone>
      <email>hsknana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyo-Seok Na, pf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 30, 2016</lastchanged_date>
  <firstreceived_date>October 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
